Lenalidomide-5-aminomethyl is primarily used in the development of pharmaceutical compounds, particularly in the treatment of certain cancers and autoimmune diseases. Its structure allows it to act as an immunomodulatory agent, enhancing the immune system's ability to target and destroy malignant cells. It is often incorporated into drug formulations designed to treat multiple myeloma, a type of blood cancer, and myelodysplastic syndromes, which are disorders affecting blood cell production. Additionally, its properties make it a candidate for research in therapies aimed at reducing inflammation and modulating immune responses in autoimmune conditions. Its role in inhibiting angiogenesis, the formation of new blood vessels that supply tumors, further underscores its importance in oncology. Researchers also explore its potential in combination therapies to improve efficacy and reduce resistance in cancer treatment.